ibuprofen has been researched along with Duodenal Ulcer in 24 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
Duodenal Ulcer: A PEPTIC ULCER located in the DUODENUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed two 24-week double-blind trials (REDUCE-1 and -2 (Registration Endoscopic Studies to Determine Ulcer Formation of HZT-501 Compared with Ibuprofen: Efficacy and Safety Studies)) to assess whether double-dose famotidine given in a single-tablet combination with ibuprofen (HZT-501) significantly reduces gastric and duodenal ulcers as compared with ibuprofen." | 9.16 | Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. ( Bello, AE; Grahn, AY; Kivitz, AJ; Laine, L; Schiff, MH; Taha, AS, 2012) |
| " Overall, the data indicate that administration of valdecoxib offers similar efficacy for the treatment of osteoarthritis but improved upper-gastrointestinal safety compared with the conventional NSAIDs, ibuprofen and diclofenac, based on the significantly lower incidence of gastroduodenal ulcers detected by endoscopy." | 9.10 | Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. ( Agrawal, NM; Kent, JD; Recker, DP; Sikes, DH; Verburg, KM; Zhao, WW, 2002) |
| " We hypothesized that COX-2-specific inhibition with rofecoxib (25 mg once daily) in the treatment of patients with osteoarthritis would cause fewer gastroduodenal ulcers than an equally effective dose of ibuprofen (800 mg 3 times a day), a nonspecific COX inhibitor." | 9.09 | A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. ( Bath, R; Bolognese, J; Harper, S; Johanson, J; Laine, L; Quan, H; Schwartz, H; Simon, T; Stern, S, 1999) |
| "Although anti-inflammatory doses of ibuprofen are very effective in treating the signs and symptoms of osteoarthritis (OA), they come with an increased risk for gastrointestinal damage which can limit their use and decrease patient adherence to therapy." | 8.90 | Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials. ( Bello, AE; Grahn, AY; Holt, RJ; Kent, JD; Rice, P, 2014) |
| "Ibuprofen/famotidine was generally well tolerated, with a tolerability profile consistent with those established for the individual agents." | 6.49 | Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. ( Deeks, ED, 2013) |
| "We performed two 24-week double-blind trials (REDUCE-1 and -2 (Registration Endoscopic Studies to Determine Ulcer Formation of HZT-501 Compared with Ibuprofen: Efficacy and Safety Studies)) to assess whether double-dose famotidine given in a single-tablet combination with ibuprofen (HZT-501) significantly reduces gastric and duodenal ulcers as compared with ibuprofen." | 5.16 | Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. ( Bello, AE; Grahn, AY; Kivitz, AJ; Laine, L; Schiff, MH; Taha, AS, 2012) |
| "Patients with osteoarthritis (age, >or=50 y) were randomized to receive lumiracoxib 400 mg once daily, naproxen 500 mg twice daily, or ibuprofen 800 mg 3 times daily for 12 months." | 5.12 | Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. ( Gitton, X; Hawkey, CJ; Krammer, G; Matchaba, P; Mellein, B; Richard, D; Sallstig, P; Smalley, W; Stricker, K; Weinstein, WM, 2007) |
| " Overall, the data indicate that administration of valdecoxib offers similar efficacy for the treatment of osteoarthritis but improved upper-gastrointestinal safety compared with the conventional NSAIDs, ibuprofen and diclofenac, based on the significantly lower incidence of gastroduodenal ulcers detected by endoscopy." | 5.10 | Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. ( Agrawal, NM; Kent, JD; Recker, DP; Sikes, DH; Verburg, KM; Zhao, WW, 2002) |
| " We hypothesized that COX-2-specific inhibition with rofecoxib (25 mg once daily) in the treatment of patients with osteoarthritis would cause fewer gastroduodenal ulcers than an equally effective dose of ibuprofen (800 mg 3 times a day), a nonspecific COX inhibitor." | 5.09 | A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. ( Bath, R; Bolognese, J; Harper, S; Johanson, J; Laine, L; Quan, H; Schwartz, H; Simon, T; Stern, S, 1999) |
| "This randomized, double-blind study tested the hypothesis that rofecoxib, a drug that specifically inhibits cyclooxygenase 2, would cause fewer gastroduodenal ulcers than ibuprofen (in a multicenter trial), and its side effects would be equivalent to those of placebo (in a prespecified analysis combining the results with another trial of identical design)." | 5.09 | Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multina ( Acevedo, E; Beaulieu, A; Bolognese, J; Hawkey, C; Laine, L; Maldonado-Cocco, J; Mortensen, E; Quan, H; Shahane, A; Simon, T, 2000) |
| "Although anti-inflammatory doses of ibuprofen are very effective in treating the signs and symptoms of osteoarthritis (OA), they come with an increased risk for gastrointestinal damage which can limit their use and decrease patient adherence to therapy." | 4.90 | Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials. ( Bello, AE; Grahn, AY; Holt, RJ; Kent, JD; Rice, P, 2014) |
| "The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and to decrease the risk of developing gastric and duodenal ulcers in patients at risk for NSAID-associated ulcers." | 3.77 | A fixed-dose combination ibuprofen and famotidine (Duexis). ( , 2011) |
| "Ibuprofen/famotidine was generally well tolerated, with a tolerability profile consistent with those established for the individual agents." | 2.49 | Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. ( Deeks, ED, 2013) |
| " Although this study failed to describe a dose-response relationship, it appears that there are significant breed differences in susceptibility to GIU subsequent to ibuprofen exposure." | 1.30 | A case-control study of acute ibuprofen toxicity in dogs. ( Hungerford, LL; Poortinga, EW, 1998) |
| " Duodenal mucosal injury, with or without gastric lesions, related to long-term use of anti-inflammatory drugs such as aspirin, indomethacin, ibuprofen, diclofenac or others are reported in three patients, in which the diagnosis was confirmed by emergency endoscopy after hematemesis." | 1.26 | Duodenal mucosal damage associated with chronic use of anti-inflammatory drugs. ( Ikeda, S; Tanaka, M; Uchiyama, M, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.67) | 18.7374 |
| 1990's | 5 (20.83) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 8 (33.33) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Meijuan, Z | 1 |
| Yu, P | 1 |
| Yuan, J | 1 |
| Yu, T | 1 |
| Sun, D | 1 |
| Deeks, ED | 1 |
| Bello, AE | 3 |
| Kent, JD | 3 |
| Grahn, AY | 2 |
| Rice, P | 1 |
| Holt, RJ | 2 |
| Caunedo-Alvarez, A | 1 |
| Gómez-Rodríguez, BJ | 1 |
| Romero-Vázquez, J | 1 |
| Argüelles-Arias, F | 1 |
| Romero-Castro, R | 1 |
| García-Montes, JM | 1 |
| Pellicer-Bautista, FJ | 1 |
| Herrerías-Gutiérrez, JM | 1 |
| Lim, EJ | 1 |
| Laine, L | 3 |
| Kivitz, AJ | 1 |
| Schiff, MH | 1 |
| Taha, AS | 1 |
| Chan, FK | 1 |
| Sikes, DH | 1 |
| Agrawal, NM | 1 |
| Zhao, WW | 1 |
| Recker, DP | 1 |
| Verburg, KM | 1 |
| Hunt, RH | 1 |
| Harper, S | 2 |
| Callegari, P | 1 |
| Yu, C | 1 |
| Quan, H | 4 |
| Evans, J | 1 |
| James, C | 1 |
| Bowen, B | 1 |
| Rashid, F | 1 |
| Shostak, NA | 1 |
| Riabkova, AA | 1 |
| Savel'ev, VS | 1 |
| Maliarova, LP | 1 |
| Clarke, SF | 1 |
| Arepalli, N | 1 |
| Armstrong, C | 1 |
| Dargan, PI | 1 |
| Hawkey, CJ | 1 |
| Weinstein, WM | 1 |
| Smalley, W | 1 |
| Gitton, X | 1 |
| Sallstig, P | 1 |
| Stricker, K | 1 |
| Krammer, G | 1 |
| Mellein, B | 1 |
| Richard, D | 1 |
| Matchaba, P | 1 |
| Bunton, RW | 1 |
| Barrett, DC | 1 |
| Palmer, DG | 1 |
| Poortinga, EW | 1 |
| Hungerford, LL | 1 |
| Lanza, FL | 1 |
| Rack, MF | 1 |
| Simon, TJ | 1 |
| Bolognese, JA | 1 |
| Hoover, ME | 1 |
| Wilson, FR | 1 |
| Harper, SE | 1 |
| Simon, T | 2 |
| Bath, R | 1 |
| Johanson, J | 1 |
| Schwartz, H | 1 |
| Stern, S | 1 |
| Bolognese, J | 2 |
| Kaufman, DW | 1 |
| Kelly, JP | 1 |
| Wiholm, BE | 1 |
| Laszlo, A | 1 |
| Sheehan, JE | 1 |
| Koff, RS | 1 |
| Shapiro, S | 1 |
| Hawkey, C | 1 |
| Beaulieu, A | 1 |
| Maldonado-Cocco, J | 1 |
| Acevedo, E | 1 |
| Shahane, A | 1 |
| Mortensen, E | 1 |
| Paroli, E | 1 |
| Nencini, P | 1 |
| Anania, MC | 1 |
| Tanaka, M | 1 |
| Uchiyama, M | 1 |
| Ikeda, S | 1 |
| Skriabin, ON | 1 |
| Baranchuk, VN | 1 |
| Manyshev, VG | 1 |
| Kurygin, AA | 1 |
| Somerville, K | 1 |
| Faulkner, G | 1 |
| Langman, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment[NCT00450658] | Phase 3 | 627 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment[NCT00450216] | Phase 3 | 906 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The secondary efficacy endpoint was the number of subjects with duodenal ulcer at any time throughout the 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 3 |
| Ibuprofen | 9 |
The secondary efficacy endpoint was the number of subjects with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 37 |
| Ibuprofen | 34 |
The primary efficacy endpoint was the number of subjects with upper gastrointestinal (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 40 |
| Ibuprofen | 38 |
The secondary efficacy endpoint was the number of subjects developing a NSAID-associated serious GI complication at any time throughout 6 months of treatment. A NSAID-associated serious GI complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or GI bleeding. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 0 |
| Ibuprofen | 0 |
The secondary efficacy endpoint was the number of participants with duodenal ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 8 |
| Ibuprofen | 14 |
The primary efficacy endpoint was the number of participants with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 55 |
| Ibuprofen | 52 |
The secondary efficacy endpoint was the number of participants with UGI (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 63 |
| Ibuprofen | 61 |
The secondary efficacy endpoint was the number of participants developing a NSAID-associated serious gastrointestinal complication at any time throughout 24 weeks of treatment. A NSAID-associated serious gastrointestinal complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or gastrointestinal bleeding. (NCT00450216)
Timeframe: 24 weeks
| Intervention | particpants (Number) |
|---|---|
| HZT-501 | 3 |
| Ibuprofen | 0 |
2 reviews available for ibuprofen and Duodenal Ulcer
| Article | Year |
|---|---|
Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Drug Interactions; Duodenal Ulcer; Famot | 2013 |
Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Combinations; Duodenal Ulcer; Famot | 2014 |
8 trials available for ibuprofen and Duodenal Ulcer
| Article | Year |
|---|---|
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2012 |
Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cyclo | 2002 |
Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase | 2003 |
Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
Topics: Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclof | 2007 |
Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenas | 1999 |
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.
Topics: Aged; Aged, 80 and over; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; D | 1999 |
Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multina
Topics: Cyclooxygenase Inhibitors; Double-Blind Method; Duodenal Ulcer; Duodenum; Enzyme Inhibitors; Gastric | 2000 |
14 other studies available for ibuprofen and Duodenal Ulcer
| Article | Year |
|---|---|
Stomach ulcer caused by mistakenly oral medication of 14,400 mg ibuprofen: A case report.
Topics: Adult; Duodenal Ulcer; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylo | 2023 |
Macroscopic small bowel mucosal injury caused by chronic nonsteroidal anti-inflammatory drugs (NSAID) use as assessed by capsule endoscopy.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Capsule Endoscopy; Cyclooxygenase 2 Inhibitors | 2010 |
Education and imaging. Gastrointestinal: Ibuprofen-induced duodenal stricture resulting in malnutrition.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Duodenal Obstruction; Duodenal Ulcer; Duoden | 2010 |
A fixed-dose combination ibuprofen and famotidine (Duexis).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Combinations; Duodenal Ulcer; F | 2011 |
Editorial: single-tablet ibuprofen/double-dose famotidine for reduction of gastric and duodenal ulcers (REDUCE Trials): what can be reduced?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Female; Huma | 2012 |
[Gastrointestinal hemorrhages as complications of gastropathies associated with intake of nonsteroidal anti-inflammatory drugs].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diclofenac; Duodenal Ulcer; Duodeno | 2003 |
Duodenal perforation after ibuprofen overdose.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Drug Overdose; Duodenal Diseases; Duodenal Ulce | 2004 |
Reintroduction of anti-inflammatory drug therapy after drug-associated gastro-intestinal disturbances.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Arthritis; Duodenal Ulcer; Female; Gastrointes | 1982 |
A case-control study of acute ibuprofen toxicity in dogs.
Topics: Acute Kidney Injury; Animals; Case-Control Studies; Dog Diseases; Dogs; Duodenal Ulcer; Female; Gast | 1998 |
The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption.
Topics: Acute Disease; Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Contro | 1999 |
Correlations of DNA, RNA and protein levels in duodenal mucosa with antiinflammatory potency and disposition to gut damage of non-steroidal agents. Comparative behaviour of glucametacine, indometacin, phenylbutazone and ibuprofen.
Topics: Animals; Anti-Inflammatory Agents; DNA; Duodenal Ulcer; Duodenum; Female; Gastrointestinal Hemorrhag | 1978 |
Duodenal mucosal damage associated with chronic use of anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents; Aspirin; Diclofenac; Duodenal Ulcer; Endoscopy; Female; Fiber Optic | 1977 |
[The results of the endoscopic diathermy coagulation of hemorrhaging gastroduodenal ulcers].
Topics: Acute Disease; Duodenal Ulcer; Electrocoagulation; Female; Hemostasis, Endoscopic; Humans; Ibuprofen | 1992 |
Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Duodenal Ulcer; Female; Humans; Ibuprofen; Indome | 1986 |